QUEST DIAGNOSTICS INC
No SEC Form 4 filings for $DGX in the last 30 days.
Quest Diagnostics director Robert B. Carter was granted 1,142 restricted stock units (RSUs) on May 20, 2026, as reported in a Form 4 SEC filing. This equity award, valued at $0.00 per share, is a compensation-related grant and not an open-market purchase. Following this transaction, Carter directly holds a total of 3,853 shares of Quest Diagnostics common stock.
Quest Diagnostics (DGX) held its 2026 Annual Meeting of Stockholders on May 20, 2026. Key outcomes included the election of directors, approval of executive officer compensation, and ratification of PricewaterhouseCoopers as the independent accounting firm. A proposal for an independent board chairman was not approved, reflecting the company's commitment to governance and transparency.
Labcorp has launched MyLabcorp™, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The app integrates lab results, AI-enabled insights, and educational content, leveraging OpenAI models for personalized explanations and conversational interactions. It aims to empower users with better health context and support more informed discussions with healthcare providers, all within a secure, HIPAA-compliant environment.
